Negative impact of Brexit on UK healthcare
Data and analytics company GlobalData has found that the impact of Brexit on the UK healthcare sector has increased over the last three months. The company’s latest report ‘Brexit and the Healthcare Industry – Implications for Pharma, Q3 2018’ has found that 59 per cent of healthcare industry professionals now have a negative sentiment about Brexit’s impact on the UK healthcare sector, compared to only 42 per cent who expressed the same opinion in June 2018.
The survey involved healthcare professionals from the US, UK and EU. EU respondents expressed the biggest fall in Brexit confidence, with a 28 per cent increase in negative sentiment since the previous survey. “One potential explanation for the increase in negative sentiment in Q3 is less clarity over the future of Brexit, especially in the EU. The Brexit process has a long way to go and is filled with uncertainty as a 'no deal' Brexit becomes an increasing possibility,” said Alexandra Annis, MS, Managing Healthcare Analyst at GlobalData. “Given the importance of the pharmaceutical industry to the UK economy, the current negativity around Brexit must be of concern. Understanding the impact of Brexit on research and manufacturing, corporate strategy, and relocation as well as tracking the evolving sentiment of Brexit’s impact on the UK healthcare industry is of significant importance to help pharmaceutical companies make the most of Britain leaving the EU.”